July 2011

Disclaimer

Neither this presentation nor any of its contents are to be distributed to third parties without the prior written consent of China Health Labs & Diagnostics Ltd. (“China Health Labs”). This presentation supersedes and replaces any and all material s which may have been provided to potential investors. There are certain risks inherent in an investment in the securities of China Health Labs, which prospective investors should carefully consider before investing in the securities of China Health Labs. Reference is made to the section entitled “Risk Factors” in the draft Filing Statement of China Health Labs dated May 30, 2010, which section is incorporated by reference into this investor presentation, for a discussion of the risks inherent in an investment in the securities of China Health Labs. The draft Filing Statement is available on SEDAR at www.sedar.com under China Health Labs’s profile.

This presentation is not, and under no circumstances is it to be construed as, an advertisement or a public offering of these securities. This presentation is personal to each offeree and does not constitute an offer to any other person or to the public generally to subscribe for or otherwise acquire any of the securities referred to herein. No securities regulatory authority or similar authority has reviewed or in any way passed upon the presentation or the merits of these securities and any representation to the contrary is an offence. This presentation has been prepared for information purposes only in order to assist prospective investors in evaluating an investment in China Health Labs.

Except for the statements of historical fact, the information contained herein may be of a forward-looking nature. Such forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement of China Health Labs to be materially different from any future results, performance or achievements expressed or implied by statements containing forward-looking information. Although China Health Labs has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that statements containing forward looking information will prove to be accurate as actual

2

be as anticipated, estimated or intended. There can be no assurance that statements containing forward looking information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on statements containing forward looking information.

The information contained herein includes market and industry data that has been obtained from third party sources, including industry publications, as well as industry data prepared by China Health Labs management on the basis of its knowledge of and experience in the industry in which China Health Labs operates. Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to the accuracy or completeness of included data. China Health Labs believes that its industry data is accurate and that its estimates and assumptions are reasonable, but there is no assurance as to the accuracy or completeness of this included data. Although the data is believed to be reliable, China Health Labs has not independently verified any of the information from third party sources referred to in this presentation or ascertained the underlying economic assumptions relied upon by such sources.

Company Overview

Leading provider of total lab solutions for medical diagnostic and food safety in China

• We develop and sell proprietary total lab solutions to targeted sectors and sell diagnostic equipment & reagents to large urban hospitals

• We generate revenues from the sale of solutions and equipment, and recurring revenues from reagents and service

3

recurring revenues from reagents and service

• We manufacture our own propriety equipment and reagents in our Beijing facility

• 2010 revenue and net income growth of 41%

• Q1 2011 revenue growth of 52%

• Q1 net income growth of 283%

China: Growing Healthcare Demand

• Rapid economic growth

• Large population

• Increasing Chinese wealth

China’s GDP per Capita (in US$)

4

• Growing middle class

• Decreasing birth rates

• Increasing older population

Source: The World Bank

Transitioning into Universal Healthcare

• High cost of medical services

• Low government funding

• Large investment gap between urban and rural areas

• Insufficient healthcare services in rural areas

Market Oriented Healthcare China’s Healthcare Expenditureper Capita (in US$)

5

• Proactive government policies

• Government spending support

• Diversified medical insurance system

• Development of local clinics in urban and rural areas

Universal Healthcare

Out of Pocket Expenditure (% of private health spending)

Source: The World Bank

Large and Growing Healthcare Market

$125B

Chinese Medical Equipment Expenditure (in US$ Billions)

China’s healthcare investmentover next 3 years

Chinese HealthcareExpenditure (in US$ Billions)

6

$125B

Competitive Advantage

• First mover in providing total lab solutions instead of individual products

• Patented hardware and software: lab management system (LMS)

• Extensive experience in managing labs

7

• Extensive experience in managing labs

• Strong relations with Chinese government and customers

Target

Chinese government policy support

Chinese government budget support

8

Target Areas

Large market potential

Limited competition

Business Units

Rural Hospitals & Clinics

Military & Emergency Services

Food SafetyLarge Urban

Hospitals & Labs

New Business UnitsTraditional

Business Unit

• Established in 1993

• Steady revenue

• Established in 2008

• Strong revenue

• Established in 2007

• Strong revenue

• Established in 2008

• Strong revenue

9

• Steady revenue stream

• Low margins

• High competition

• Strong market position

• Strong revenue potential

• High margins

• Low competition

• Strong market position

• Strong revenue stream

• High margins

• No competition

• Dominant market position

• Strong revenue potential

• High margins

• No competition

• Dominant market position

Rural Hospitals & Labs

• Proprietary total diagnostic lab solution

• Initial revenue from testing equipment, hardware, lab management system (LMS), installation and training

• Recurring revenue from reagents, service and maintenance

800millionChina’s rural population

10

• 330 installations to date

• Contract for additional 467

• Presence in Henan, Guizhou, Liaoning and Jilin provinces

• Only solution provider to have Chinese central government approval

Military & Emergency Rescue

• Point of Care Technology (POCT)

• Dry chemistry diagnostic system for use in military and rescue operations

• No electricity or clean water required

• Developed in cooperation with Chinese Military

11

Military

• Only supplier to Chinese military and Chinese National Emergency Reserve Team (NERT)

• Sold 17 units in 2009, 34 orders in 2010, 13 orders from NERT in Q1 2011

• Signed 3 year R&D agreement with Chinese military in Dec 2010

>50%Gross margin

Food Safety Labs

• Total food safety lab solutions

• Tests chemical or biochemical index of food items

• Developed with Beijing municipal government

12

• 17 large labs, 250 mini-labs and17 mobile labs installed to date in Beijing

• New lab management system (LMS) and mobile POCT products under development

• Use “Beijing Model” as reference site to sell to additional cities in China

$1billionChinese market opportunity in top 50 cities

Large Urban Hospitals

• Medical diagnostic equipment

• Diagnosis of various blood, liver and kidney related diseases and conditions

• Competitive imported and locally made product range

50%Percent of 1000largest Chinesehospitals served

13

• Initial revenue from testing equipment, hardware, lab management system (LMS), installation and training

• Recurring revenue from reagents, maintenance and services

Growth Strategy

Focus on total lab solutions

Target growthareas

New & improved solutions

Acquisitions & partnerships

• Acquisition orpartnership withcomplementarybusinesses

• Continue developingsolutions in collaborationwith customers

• Provide premiumvalue compared withindividual products

• Rural areas / Military &Emergency / Food safety

• Limited competition and

14

businesses

• Target establishedbrands

• Businesses thatdeliver high qualityservices

• Joint R&D with Chinesemilitary

• Collaboration withprovincial and centralgovernment

• Build customer loyalty

• Multiple recurringrevenue streams

• Limited competition andhigh margins

• Chinese governmentsupport and budget

2010 2009 GrowthQ1

2011Q1

2010Growth

Revenue $33.7m $23.8m 41% $6.8m $4.4m 52%

Gross Profit

$13.2m $8.3m 60% $3.9m $1.4m 183%

Financials

59%

17%

15%

2010 Revenue by Sector

15

EPS $0.10 $0.07 43% $0.02 $0.01 100%

Net Income

$5.5m $3.9m 41% $1.2 m $0.3m 283%

Total Assets

$37.1m $21.4m 74% $42.7m $21.4m 100%

59%9%

large Urban Hospitals & Labs

Rural Hospitals & Clinics

Military & Emergency Services

Food Safety

Location & Distribution

BeijingHQ & Production Facility

Guangdong

16

GuangdongSales & Distribution Hub

ShanghaiSales Office

Management

Shiping (Wilson) Yao

President, CEO, Chairman and Director

Founded Biochem Group in 1993. Over 20 years experience in the medical equipment industry. Member of China’s National Standardization Technical Committee. Member of the Board of Renmin University of China

Adam Kniec

CFO

Founder of ArkOrion Enterprises Inc., a provider of accounting and financial reporting services to Canadian and US publicly traded companies

Yuqiang Tang

COO, Director

Over 15 years of managerial, sales and marketing experience

17

Bill Tunbrant

VP of Marketing, Director

Wide range of experience in the medical equipment industry, as well as in international manufacturing. Former director of Nibe Industrier AB (OMX: NIBE’B)

Chao Zhang

VP of Finance

10 years financial management experience in the medical equipment and private health care industries

Stephen D. Wortley

Secretary

Currently a partner at the law firm McMillan LLP

Non-Executive (Independent) Directors

Yumin Zhuang

Deputy Dean of the School of Finance of Renmin University. Independent supervisor with china CITI Bank.

Hong Chang

Physician with the University Health Network in Toronto

Paul Haber

Director of Migao Corporation (TSX: MGO). Former Vice President, Chief Financial Officer and Corporate Secretary of QuStream Corporation (TSXV:QVC)

Kim Oishi

Director of Zongshen PEM Power Systems (TSX: ZPP). Former President and Director of Hanfeng Evergreen (TSX: HF), Senior Vice President of

18

Director of Zongshen PEM Power Systems (TSX: ZPP). Former President and Director of Hanfeng Evergreen (TSX: HF), Senior Vice President of Hanwei Energy (TSX: HE), Director of Cantronic Systems (TSX-V: CTS), and Grand Power Logistics (TSX-V: GPW)

Investment Highlights

• Diversified revenue model

• Substantial recurring revenue base

• High margin business streams

19

• Limited market competition

• Chinese government expenditure and policy support

• Sufficient funding to continue growth in 2011

Corporate Information

TSX.V Symbol: CHO

52 Week Range: $0.55 - $1.56

Shares Outstanding: 65.6 Million

Market Capitalization (July 15, 2011): $59 Million

20

Market Capitalization (July 15, 2011): $59 Million

Employees: 233

July 2011

Operating as: